ClinicalTrials.gg
RecruitingNCT06817421OPTIMALUpdated Oct 8, 2026

Opportunistic Pneumococcal Immunisation Trial in MALnutrition

A Phase 4 interventional study of Pneumococcal conjugate vaccine and Typhoid conjugate vaccine in Severe Acute Malnutrition in Childhood, Pneumococcal Disease and Pneumococcal Vaccines, sponsored by Nick Fancourt. Recruiting at 1 site in Timor-Leste. Open to participants aged 6 Months to 59 Months. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Nick Fancourt · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 8, 2026Now Recruiting1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
6 Months to 59 Months
Sex
All
01

Study summary

The goal of the OPTIMAL clinical trial is to learn if a dose of a pneumococcal conjugate vaccine (PCV) generates a good immune response in young children who are in hospital with severe acute malnutrition.

Researchers will compare an intervention group who get a dose of a PCV (Pneumosil) to a control group who get a dose of a Typhoid conjugate vaccine (Typbar TCV). To ensure all participants receive timely potential benefits, at 3 months participants in the intervention group with receive a dose of Typbar TCV, and those in the conrol group will receive a dose of Pneumosil.

Participants will be visited 4 times at their homes over six months after vaccination, with a phone review at 12 months after vaccination.

Read the detailed description

This is a prospective, single-centre, double-blind, randomised controlled trial in 264 children aged 6-59 months hospitalised with severe acute malnutrition.

Participants will be randomised (1:1) to receive either a dose of a pneumococcal conjugate vaccine (Pneumosil, the intervention group) or a dose of a Typhoid conjugate vaccine (Typbar TCV, the control group). Stratification for randomisation will be done on (a) prior immunisation with a PCV (confirmed or unknown/unvaccinated); and (b) severity of malnurition (weight-for-height/length z-score \<-4 or >=-4). Participants will be enrolled as soon as practical after admission to hospital, while randomisation and vaccine administration will occur once the participant is medically stable in the 'transition phase' of SAM care.

The primary objective is to demonstrate that immune responses to the 10 pneumococcal serotypes in Pneumosil are better in participants who receive Pneumosil, compared to those who receive Typbar TCV, when measured 28 days after vaccination.

02

Conditions studied

  • Severe Acute Malnutrition in Childhood
  • Pneumococcal Disease
  • Pneumococcal Vaccines
  • Pneumococcal Infection
  • Pneumonia in Children

Keywords

  • Pneumococcal
  • Severe Acute Malnutrition in childhood
  • Pneumococcal vaccine
  • Pneumosil
  • Pneumococcal disease
  • Pneumococcal infection
  • Pneumonia
03

In context

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

This study's planned enrollment of 214 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.

Browse Pneumococcal Infections studies →

Lead sponsor

This is the only study on the registry with Nick Fancourt as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 6-59 months at the time of hospitalisation
  2. Hospitalised with severe acute malnutrition (SAM, defined as any one of a, b, or c):

    1. weight-for-length/height z-score \<-3; or
    2. middle upper arm circumference \<11.5cm; or
    3. bilateral pitting pedal oedema unexplained by other causes
  3. Parent/carer is willing for their child to participate in the study and has provided written
  4. Parent/carer is willing to comply with all study procedures outlined in the protocol, including specimen collection, for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Known history of allergy or to any component of either study vaccine, including diphtheria toxoid, or a history of anaphylactic shock.
  2. Treatment with another drug or other intervention in the 30 days prior to randomisation, or ongoing participation in another clinical trial.
  3. Suspected primary or secondary immunodeficiency or prolonged administration (>14 days) of an immune modifying drug (including oral ) in the past 3 months.
  4. Known terminal illness expected to result in death within 6 months.
  5. Participants who, in the opinion of the site Principal Investigator, are unable to comply with the study protocol, including scheduled visits, assessments, and any other protocol-required procedures.
  6. Previously enrolled in this trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (estimated)

Study arms

  • Experimental
    Treatment Arm: Pneumosil

    Biological: Pneumococcal conjugate vaccine

  • Other
    Control Arm: Typbar TCV

    Biological: Typhoid conjugate vaccine

Interventions

  • 10-valent pneumococcal polysaccharide conjugate vaccine at a dosage of 2μg for each serotype polysaccharide for 1, 5, 6A, 7F, 9V, 14, 19A, 19F, 23F, and 4μg for serotype 6B, conjugated to a carrier protein (CRM197), polysorbate 20 and aluminium phosphate as an adjuvant. Administered as an intramuscular injection of 0.5mL.

  • BiologicalTyphoid conjugate vaccine

    Typhoid conjugate vaccine at a dosage of 25μg purified Vi capsular polysaccharide of Salmonella typhi Ty2 conjugated to Tetanus Toxoid with preservative (2-Phenoxyethanol). Administered as an intramuscular injection of 0.5mL.

06

What researchers measure

Primary outcomes

  1. Serotype-specific immunoglobulin G (IgG) antibodies

    Pneumosil serotype-specific (1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 23F) immunoglobulin G (IgG) geometric mean concentrations (GMCs).

    Time frame: 4 weeks after vaccination

Secondary outcomes

  1. Serotype-specific IgG antibodies

    Pneumosil serotype-specific IgG GMCs

    Time frame: 4 weeks and 3 months after vaccination

  2. Proportion of participants with serotype-specific IgG antibody responses ≥ 0.35 μg/mL

    Proportion of participants with Pneumosil serotype-specific IgG concentrations ≥ 0.35μg/mL

    Time frame: 4 weeks and 3 months after vaccination

  3. Functional antibody responses

    Pneumosil serotype-specific pneumococcal geometric mean opsonisation indices (GMOIs)

    Time frame: 4 weeks and 3 months after vaccination

  4. Functional antibody responses

    Proportion of participants with Pneumosil serotye-specfiic pneumococcal opsonisation indices (OIs) \>8

    Time frame: 4 weeks and 3 months after vaccination

  5. Salivary IgG antibodies

    Serotype-specific salivary IgG (μg/ml) for Pneumosil serotypes and non-vaccine types 3, 4, 11A, and 18C

    Time frame: 4 weeks and 3 months after vaccination

  6. Salivary immunoglobulin A (IgA) antibodies

    Serotype-specific salivary IgA (μg/ml) for Pneumosil serotypes and non-vaccine types 3, 4, 11A, and 18C

    Time frame: 4 weeks and 3 months after vaccination

  7. Nasopharyngeal carriage of pneumococcus

    Proportion of participants with nasopharyngeal carriage of Pneumosil vaccine-type pneumococci and their antimicrobial resistance patterns

    Time frame: 3 months after vaccination

  8. Severe acute malnutrition recovery

    Weight-for-height/length z-score \>= -2 or MUAC \>12.5cm

    Time frame: Reviewed at all study visits until completion (12 months after vaccination)

  9. Re-hospitalisation

    Any repeat admission to hospital as confirmed by medical records

    Time frame: 3 months and 12 months after vaccination

  10. Mortality

    Deaths as reported. Cause of death determined from review of medial records.

    Time frame: 3 and 12 months after vaccination

  11. Composite illness or mortality

    Repeat hospitalisation(s) or death.

    Time frame: Reviewed at all study visits until completion (12 months after vaccination)

  12. Salmonella Typhi antibodies

    Proportion of paticipants with \>4 fold rise (compared to pre-vaccination) of Salmonella Typhi anti-Vi IgG geometric mean titres (GMTs)

    Time frame: 4 weeks and 3 months after vaccination for all participants, plus 4 months and 6 months after vaccination for participants in the control arm

07

Study locations

1 of 1 sites recruiting
  • Guido Valadares National Hospital (HNGV)
    Dili, Timor-Leste
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Plan for IPD sharing is in development.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.

Of 21 phase 4 interventional studies under Pneumococcal Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's planned 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 10, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Feb 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
1 site added, 1 site removed
Show site
  • Guido Valadares National Hospital (HNGV) · Dili, Timor-Leste
Show 1 removed
  • Guido Valadares National Hospital (HNGV) · Dili, Timor-Leste
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Guido Valadares National Hospital (HNGV) · Dili, Timor-Leste
    Show 1 removed
    • Guido Valadares National Hospital (HNGV) · Dili, Timor-Leste
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06817421
Lead sponsor
Nick Fancourt
Collaborators
Murdoch Childrens Research Institute, The University of Western Australia, University of Edinburgh, Timor-Leste Ministry of Health
Responsible party
Nick Fancourt (Senior Research Fellow, Menzies School of Health Research) — Sponsor-investigator
First posted
Feb 10, 2025
Start date
Jan 16, 2026
Primary completion
Mar 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Nicholas S. S. Fancourt, PhD
Contact
nick.fancourt@menzies.edu.au
+61889468600
Jane N Nelson, Bachelor of Nursing
Contact
jane.nelson@menzies.edu.au
+61889468600

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal Conjugate Vaccine

Start the discussion